Literature DB >> 26335892

Clinical features and outcome of patients with descending necrotizing mediastinitis: prospective analysis of 34 cases.

Daniela M Palma1, Simone Giuliano2, Andrea N Cracchiolo1, Marco Falcone2, Giancarlo Ceccarelli2, Romano Tetamo1, Mario Venditti3.   

Abstract

PURPOSE: We aimed to investigate clinical features of patients with descending necrotizing mediastinitis (DNM) in order to improve management and outcome.
METHODS: We prospectively examined all patients with DNM admitted to the Intensive Care Unit (ICU) during the period from April 2007 to December 2013. Demographics, clinical features, microbiology, medical and surgical treatment data were recorded. Survivor and nonsurvivor groups were analyzed to identify factors associated with mortality.
RESULTS: Overall, 34 patients with DNM have been included. The mean age was 46.8 ± 11.2 years (range 24-70). The male/female ratio was 3.25. DNM arose from odontogenic infection in 22 (65%) patients; from peritonsillar abscess in 9 (26%) patients and from paranasal sinus in 3 (9%) patients. Microbiological cultures revealed a high percentage of aerobic/anaerobic coinfection. Nonsurvivors were statistically more likely to have higher SAPS II score (mean difference 19.1, 95% CI 12.3-25.9 P < 0.01) and more severe disease (P < 0.01) than survivors. Positive correlation was found between time to ICU admission after head or neck infection diagnosis and SAPS II score (ρ = 0.5, P = 0.03). The same was true for ICU length of stay and time to ICU admission (ρ = 0.6, P < 0.01) and time to surgery (ρ = 0.5, P = 0.03). Surgical treatments consisted in: transcervical drainage in 14 cases, (42%); irrigation through subxiphoid and cervical incisions of the anterior mediastinum with additional percutaneous thoracic drainage when necessary in ten cases, (29 %); thoracotomy with radical mediastinal surgical debridement, excision of necrotic tissue and decortication in ten cases, (29%). We have found a mortality rate of 12%. Patients with DNM type IIB were admitted to the ICU later than patients with DNM type I and type IIA (mean difference 3.2 days, 95% CI 1.2-5.1, P 0.02).
CONCLUSIONS: Prompt ICU admission in order to manage severe sepsis and/or septic shock, along with early and aggressive surgery and adequate antimicrobial therapy, could be key factors in reducing DNM mortality.

Entities:  

Keywords:  Anaerobes; Daptomycin; Descending necrotizing mediastinitis; Facultative anaerobes; Head and neck infections; Piperacillin-tazobactam; Sepsis; Septic shock

Mesh:

Substances:

Year:  2015        PMID: 26335892     DOI: 10.1007/s15010-015-0838-y

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  42 in total

1.  Breakthrough bacteremia and septic shock due to Streptococcus anginosus resistant to daptomycin in a patient receiving daptomycin therapy.

Authors:  Federico Palacio; James S Lewis; Lee Sadkowski; Kelly Echevarria; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

Review 2.  Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: new insights and evidence from the literature.

Authors:  Marco Falcone; Alessandro Russo; Mario Venditti
Journal:  J Infect Chemother       Date:  2015-03-06       Impact factor: 2.211

3.  Determining optimum management of descending necrotizing mediastinitis with CT; experience with 32 cases.

Authors:  Mariano Scaglione; Antonio Pinto; Stefania Romano; Sabrina Giovine; Amelia Sparano; Luigia Romano
Journal:  Emerg Radiol       Date:  2005-05-14

4.  Descending necrotizing mediastinitis.

Authors:  A S Estrera; M J Landay; J M Grisham; D P Sinn; M R Platt
Journal:  Surg Gynecol Obstet       Date:  1983-12

5.  Improved results from a standardized approach in treating patients with necrotizing fasciitis.

Authors:  L A Sudarsky; J C Laschinger; G F Coppa; F C Spencer
Journal:  Ann Surg       Date:  1987-11       Impact factor: 12.969

6.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality.

Authors:  Chin-Ho Wong; Haw-Chong Chang; Shanker Pasupathy; Lay-Wai Khin; Jee-Lim Tan; Cheng-Ooi Low
Journal:  J Bone Joint Surg Am       Date:  2003-08       Impact factor: 5.284

8.  Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?

Authors:  Marco Falcone; Alessandro Russo; Maria Iris Cassetta; Angela Lappa; Luigi Tritapepe; Gabriella d'Ettorre; Stefania Fallani; Andrea Novelli; Mario Venditti
Journal:  J Infect Chemother       Date:  2013-01-30       Impact factor: 2.211

Review 9.  The role of encapsulated anaerobic bacteria in synergistic infections.

Authors:  I Brook
Journal:  FEMS Microbiol Rev       Date:  1994-01       Impact factor: 16.408

10.  Mediastinitis from odontogenic and deep cervical infection. Anatomic pathways of propagation.

Authors:  R Moncada; R Warpeha; J Pickleman; M Spak; M Cardoso; A Berkow; H White
Journal:  Chest       Date:  1978-04       Impact factor: 9.410

View more
  14 in total

Review 1.  [Surgical treatment of acute mediastinitis].

Authors:  M Krüger; S Decker; J P Schneider; A Haverich; O Schega
Journal:  Chirurg       Date:  2016-06       Impact factor: 0.955

2.  Fatal case of descending necrotising mediastinitis.

Authors:  Rie Sato; Takashi Watari; Yasuharu Tokuda
Journal:  BMJ Case Rep       Date:  2017-07-13

3.  Unveiling the Pathogenic Bacteria Causing Descending Necrotizing Mediastinitis.

Authors:  Qiang Sun; Zixuan Li; Panpan Wang; Junfang Zhao; Shuai Chen; Minglei Sun
Journal:  Front Cell Infect Microbiol       Date:  2022-06-08       Impact factor: 6.073

Review 4.  [Acute and chronic mediastinitis].

Authors:  J Kluge
Journal:  Chirurg       Date:  2016-06       Impact factor: 0.955

5.  Descending necrotizing mediastinitis in the elderly patients.

Authors:  Antonio Mazzella; Mario Santagata; Atirge Cecere; Ettore La Mart; Alfonso Fiorelli; Gianpaolo Tartaro; Domenico Tafuri; Domenico Testa; Edoardo Grella; Fabio Perrotta; Andrea Bianco; Gennaro Mazzarella; Mario Santini
Journal:  Open Med (Wars)       Date:  2016-11-19

6.  Descending necrotizing mediastinitis in a healthy young adult.

Authors:  Nobuaki Ochi; Tokio Wakabayashi; Atsushi Urakami; Tomoki Yamatsuji; Naoto Ikemoto; Yasunari Nagasaki; Nozomu Nakagawa; Yoshihiro Honda; Hidekazu Nakanishi; Hiromichi Yamane; Yasumasa Monobe; Takeshi Akisada; Hiroshi Katayama; Yoshio Naomoto; Nagio Takigawa
Journal:  Ther Clin Risk Manag       Date:  2018-10-17       Impact factor: 2.423

7.  Multidisciplinary treatment of deep neck infection associated with descending necrotizing mediastinitis: a single-centre experience.

Authors:  Chao Ma; Lian Zhou; Ji-Zhi Zhao; Run-Tai Lin; Tao Zhang; Li-Jiang Yu; Tian-Yin Shi; Mu Wang
Journal:  J Int Med Res       Date:  2019-10-23       Impact factor: 1.671

8.  Distribution of descending necrotizing mediastinitis and efficacy of distribution-specific drainage.

Authors:  Motoki Yano; Hiroki Numanami; Takashi Akiyama; Rumiko Taguchi; Chihiro Furuta; Tetsuya Ogawa; Mayuko Kishimoto; Hiroki Okamoto; Daisuke Inukai; Masayuki Haniuda
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895

9.  Microbiome of Odontogenic Abscesses.

Authors:  Sebastian Böttger; Silke Zechel-Gran; Daniel Schmermund; Philipp Streckbein; Jan-Falco Wilbrand; Michael Knitschke; Jörn Pons-Kühnemann; Torsten Hain; Markus Weigel; Hans-Peter Howaldt; Eugen Domann; Sameh Attia
Journal:  Microorganisms       Date:  2021-06-16

Review 10.  Complications of peritonsillar abscess.

Authors:  Tejs Ehlers Klug; Thomas Greve; Malene Hentze
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-07-30       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.